Alkermes Inc

Type: Company
Name: Alkermes Inc
Nationality: United States
Web Address: http://www.alkermes.com/
Fact Sheet: Fact Sheet for Alkermes Inc
First reported Aug 21 2014 - Updated Aug 22 2014 - 1 reports

Alkermes reports lower Q2 net income, updates annual guidance

Alkermes plc, a biopharmaceutical company, has reported that net income for the second quarter ended June 30, 2014 was $3.73 million, or $0.02 per diluted share, compared to $7.33 million, or $0.05 per diluted share, for the same quarter ended June 30, ... [Published Individual.com - Aug 21 2014]
First reported Aug 19 2014 - Updated Aug 20 2014 - 2 reports

Alkermes (ALKS) Showing Neutral Technicals With Support At $42.37

The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered-call trade on Alkermes Inc (ALKS) that includes 6.70% downside protection. Sell one contract of the Nov. '14 ... [Published MarketIntelligenceCenter.com - Aug 20 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 2 reports

Treatment Research Institute Names Gastfriend CEO Chair of the Board

TRI reported that Dr. Gastfriend previously held the position of Vice President for Scientific Communications at Alkermes. According to a release from TRI, concurrently, A. Thomas McLellan, Ph.D., founder of the Treatment Research Institute, will assume ... [Published Insurance News Net - Aug 20 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Endo appoints Shane M. Cooke to Board of Directors

SOURCE Endo International plcDUBLIN"I am excited to welcome Shane to our board of directors," said Roger KimmelMr. Cooke joined Alkermes as president upon completion of the merger between Elan Drug Technologies (EDT) and Alkermes, Inc. in September 2 ... [Published KEYC Television - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 3 reports

Alkermes Makes a Move: Up 2.4%

Up 2.4% to $43.98, Alkermes (NASDAQ:ALKS), is one of today's notable movers. The Dow is up 0.9% to 16,821 and the S&P is currently up 0.8% to 1,971. ... [Published Individual.com - Aug 18 2014]
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

Post Earnings Update: Alkermes Has Climbed 0.4% Higher in Past 2 Weeks (ALKS)

When Alkermes (NASDAQ:ALKS) reported earnings 18 days ago on July 31st, 2014, analysts, on average, expected the company to report earnings of $0.14 on sales of $147.7 million. Alkermes actually reported a loss of $0.10 per share on sales of $153.4 million, ... [Published Individual.com - Aug 18 2014]
Entities: Alkermes Inc, NASDAQ
First reported Aug 15 2014 - Updated Aug 15 2014 - 3 reports

Alkermes (ALKS) Showing Support Near $41.17

The patented algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center found a trading opportunity with Alkermes Inc (http://www.marketintelligencecenter.com/symbol/ALKS"ALKS) that should provide a 8.88% return in just 99 days. ... [Published Individual.com - Aug 15 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 3 reports

Alkermes' (ALKS) CEO Richard Pops on Q2 2014 Results - Earnings Call Transcript

OperatorLadies and gentlemen, thank you for standing-by and welcome to the Alkermes Conference Call to discuss the Company's financial results for the Second Quarter of 2014. At this time, all participants are in a listen-only mode. (Operator Instruction). ... [Published Seeking Alpha - Jul 31 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 3 reports

Alkermes Reports Q2 Non-GAAP EPS Of $0.11; Updates FY14 Guidance

Alkermes plc (ALKS: Quote) reported second-quarter net income of $3.7 million, or $0.02 per share, compared to $7.3 million, or $0.05 per share, prior year. The company noted that the results included a gain of $15.3 million related to the sale of Alkermes' ... [Published RTTNews.com - Jul 31 2014]
First reported Jul 30 2014 - Updated Jul 31 2014 - 7 reports

Alkermes begins FORWARD-5 pivotal programme of ALKS 5461 for major depressive disorder

Biopharmaceutical company Alkermes (NasdaqGS:ALKS) reported on Wednesday the launch of three planned core efficacy studies in the pivotal clinical programme for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD), the FORWARD-5. ... [Published Individual.com - Jul 31 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 2 reports

Alkermes (ALKS) Trading Near $46.70 Resistance Level

Jul 25, 2014 (Marketintelligencecenter.com via COMTEX News Network) -- Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with Alkermes Inc ( ALKS ) that should provide a 11.08% return in just 120 days. ... [Published PredictWallStreet - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 3 reports

Alkermes plc To Host Conference Call To Discuss Second Quarter 2014 Financial Results

Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, July 31, 2014, to discuss the company’s financial results for the second quarter of 2014. Management will review the quarter and provide an update on ... [Published BioSpace - Jul 25 2014]

Quotes

James Frates, CFO of Alkermes said: "These quarterly results reflect the strength of our commercial business and the progress we are making to advance Alkermes' pipeline of innovative CNS medicines. We expect this valuable, late-stage pipeline to fuel significant future growth, and we are in the strong position to drive new productproduct development with robust and reliable revenue streams and significant cash on the balance sheet. Today, we are updating our financial expectations for 2014 to reflect our results year-to-date and investment in R&D activities that have accelerated since we originally provided expectations in February."
...to welcome David Gastfriend as CEO of the Treatment Research Institute," said Carolyn Asbury, Ph D , Chair of the TRI Board for more than 10 years. "David is an internationally respected scientist, clinician and business leader. He brings extensive expertise that will help guide TRI's growth and strengthen its impact in the era of healthcare reform."
Alkermes Inc (http://www.marketintelligencecenter.com/symbol/ALKS "ALKS) presents a trading opportunity that offers a 9.38% return in just 95 days."
"I am excited to welcome Shane to our board of directors" said Roger Kimmel

More Content

All (269) | News (105) | Reports (0) | Blogs (153) | Audio/Video (0) | Fact Sheets (1) | Press Releases (10)
sort by: Date | Relevance
Alkermes Plc Given Consensus Rating of “Buy” by... [Published American Banking News - Forex - Aug 22 2014]
Alkermes (ALKS) Trading Near $44.90 Resistance ... [Published MarketIntelligenceCenter.com - Aug 22 2014]
Potential Alkermes (ALKS) Trade Has 4.08% Downs... [Published MarketIntelligenceCenter.com - Aug 21 2014]
Alkermes reports lower Q2 net income, updates a... [Published Individual.com - Aug 21 2014]
Alkermes (ALKS) Showing Neutral Technicals With... [Published MarketIntelligenceCenter.com - Aug 20 2014]
Treatment Research Institute Names Gastfriend C... [Published Insurance News Net - Aug 20 2014]
Treatment Research Institute Names Gastfriend C... [Published Individual.com - Aug 20 2014]
Potential Alkermes (ALKS) Trade Has 6.48% Downs... [Published Individual.com - Aug 19 2014]
Potential Alkermes (ALKS) Trade Has 6.48% Downs... [Published MarketIntelligenceCenter.com - Aug 19 2014]
Endo appoints Shane M. Cooke to Board of Directors [Published KEYC Television - Aug 19 2014]
Alkermes Makes a Move: Up 2.4% [Published Individual.com - Aug 18 2014]
Alkermes Makes a Move: Up 2.4%... [Published Financial News Network online - Aug 18 2014]
Alkermes (ALKS) Showing Resistance Near $44.54 [Published Individual.com - Aug 18 2014]
Post Earnings Update: Alkermes Has Climbed 0.4%... [Published Individual.com - Aug 18 2014]
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
Alkermes (ALKS) Showing Resistance Near $44.54 [Published MarketIntelligenceCenter.com - Aug 18 2014]
Earnings Look Back: Alkermes Is Up 0.4% Since R... [Published Individual.com - Aug 16 2014]
Alkermes (ALKS) Showing Support Near $41.17 [Published Individual.com - Aug 15 2014]
Alkermes (ALKS) Showing Support Near $41.17 [Published MarketIntelligenceCenter.com - Aug 15 2014]
Alkermes has the Highest Forward P/E Ratio in t... [Published Individual.com - Aug 15 2014]
Thursday's ETF Movers: BBH, GXC [Published Atlanta Journal And Constitution - Aug 14 2014]
Biotech Stock Directory Update [Published InvestorIdeas.com - Aug 14 2014]
Alkermes (ALKS) Showing Bearish Technicals With... [Published MarketIntelligenceCenter.com - Aug 14 2014]
Insider Selling: Alkermes Plc CMO Unloads 16,66... [Published American Banking News - Aug 14 2014]
Insider Selling: Alkermes Plc CFO Unloads $620,... [Published American Banking News - Aug 14 2014]
Biotech investment has increased significantly ... [Published Live-PR.com - Aug 13 2014]
Lundbeck Remains A High-Risk/High-Reward Specia... [Published Seeking Alpha - Aug 12 2014]
Alkermes (ALKS) Showing Bearish Technicals [Published MarketIntelligenceCenter.com - Aug 12 2014]
Earnings Flashback: Since Reporting Quarterly R... [Published Individual.com - Aug 11 2014]
Will threats of an inversion crackdown quash ph... [Published FiercePharma - Aug 11 2014]
1 2 3 4 5 6 7 8 9
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Alkermes (ALKS) Trading Near $44.90 Resistance ... [Published MarketIntelligenceCenter.com - Aug 22 2014]
Alkermes Inc (ALKS) presents a trading opportunity that offers a 9.21% return in just 92 days.A covered call on Alkermes at the $44.00 level expiring on Nov. '14 offers an assigned return rate of 9.21% or 36.53% annualized. This trade offers 6.61% downside ...
Potential Alkermes (ALKS) Trade Has 4.08% Downs... [Published MarketIntelligenceCenter.com - Aug 21 2014]
MarketIntelligenceCenter.com's option-trade picking algorithms have identified an attractive covered-call trade on Alkermes Inc (ALKS). Look at the Oct. '14 $45.00 covered call for a net debit in the $42.32 area. This trade has a duration of 58 days. ...
Alkermes (ALKS) Showing Neutral Technicals With... [Published MarketIntelligenceCenter.com - Aug 20 2014]
The patented option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered-call trade on Alkermes Inc (ALKS) that includes 6.70% downside protection. Sell one contract of the Nov. '14 ...
Potential Alkermes (ALKS) Trade Has 6.48% Downs... [Published MarketIntelligenceCenter.com - Aug 19 2014]
Alkermes Inc (ALKS) presents a trading opportunity that offers a 9.38% return in just 95 days.A covered call on Alkermes at the $45.00 level expiring on Nov. '14 offers an assigned return rate of 9.38% or 36.05% annualized. This trade offers 6.48% downside ...
Alkermes (ALKS) Showing Resistance Near $44.54 [Published MarketIntelligenceCenter.com - Aug 18 2014]
The patented option trade-picking algorithms behind MarketIntelligenceCenter.com's Artificial Intelligence Center have selected a covered call trade on Alkermes Inc (ALKS) that includes 5.94% downside protection. Sell one contract of the Nov. '14 $44.00 ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
Clinical Trial Data, NDA Submissions, and Board... [Published Financial Services - Jun 25 2014]
Biotech Equities Under Review -- Research on Ac... [Published Financial Services - May 09 2014]
Priority Reviews, Preliminary Earnings Releases... [Published Financial Services - Apr 11 2014]
Certifications, Authorizations, Stock Updates, ... [Published Financial Services - Apr 10 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.